Overall Survival Is Not A Required Primary Endpoint In All Cancer Trials, US FDA Says

 
• By Sue Sutter
  
Gold standard
Overall survival remains the gold standard endpoint, but need not be the primary analysis in every study. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D